Compare GMRS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMRS | CSTL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 722.8M |
| IPO Year | 2026 | 2019 |
| Metric | GMRS | CSTL |
|---|---|---|
| Price | $12.67 | $33.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | ★ 749.5K | 492.9K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $11.90 | $17.72 |
| 52 Week High | $15.98 | $44.28 |
| Indicator | GMRS | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 63.27 |
| Support Level | $12.06 | $22.88 |
| Resistance Level | $13.36 | $33.75 |
| Average True Range (ATR) | 0.96 | 1.74 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 30.99 | 75.93 |
GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs. The group provides emergent, non-emergent, disaster response, and event medical services across the healthcare ecosystem, serving local communities, health systems, payors, public health, and local, state, and federal agencies within the United States.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.